No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy: a study of the East German Study Group (OSHO) and the German CML study group.

Antineoplastic Agents / therapeutic use Chronic Disease Humans Hydroxyurea / therapeutic use Imatinib Mesylate / therapeutic use Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy Treatment Outcome
Chronic myeloid leukaemia Imatinib hydroxyurea/imatinib outcome phase I phase II

Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
12 2020
Historique:
pubmed: 17 7 2020
medline: 28 4 2021
entrez: 17 7 2020
Statut: ppublish

Résumé

The combination of Imatinib (IM) and hydroxyurea (HU) was explored for the treatment of chronic myelogenous leukemia (CML). After Additive specific inhibition of CML cells by IM/HU was detected IM/HU combination was more potent in selectively inhibiting CML cells

Identifiants

DOI: 10.1080/10428194.2020.1786556 PMID: 32672489
pubmed: 32672489
doi: 10.1080/10428194.2020.1786556
doi:

Substances chimiques

Antineoplastic Agents 0
Imatinib Mesylate 8A1O1M485B
Hydroxyurea X6Q56QN5QC

Banques de données

ClinicalTrials.gov
['NCT02480608']

Types de publication

Clinical Trial, Phase I Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

2821-2830

Auteurs

Thoralf Lange (T)

Abteilung Hämatologie und Onkologie, Universität Leipzig, Leipzig, Germany.
Krankenhaus Weißenfels, Weißenfels, Germany.

Christian Niederwieser (C)

Klinik für Stammzelltransplantation, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany.
ORCID: 0000-0002-0114-1011

Arthur Gil (A)

Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), Ludwig-Maximilians-Universität München, Munich, Germany.

Rainer Krahl (R)

Abteilung Hämatologie und Onkologie, Universität Leipzig, Leipzig, Germany.

Ulrich von Grünhagen (U)

Gemeinschaftspraxis Hämatologie und Onkologie, Cottbus, Germany.

Haifa Kathrin Al-Ali (HK)

Abteilung Hämatologie und Onkologie, Universität Leipzig, Leipzig, Germany.
Krukenberg Cancer Center, University Hospital Halle, Halle, Germany.

Kathleen Jentsch-Ullrich (K)

Gemeinschaftspraxis für Hämatologie und Onkologie, Magdeburg, Germany.

Claudia Spohn (C)

Gemeinschaftspraxis für Hämatologie und Onkologie, Halle, Germany.

Volker Lakner (V)

Gemeinschaftspraxis für Hämatologie und Onkologie, Rostock, Germany.

Michael Assmann (M)

MVZ Elblandpolikliniken GmbH, Riesa, Germany.

Christian Junghanss (C)

Medizinische Klinik III, Universität Rostock, Rostock, Germany.

Michael Cross (M)

Abteilung Hämatologie und Onkologie, Universität Leipzig, Leipzig, Germany.

Rüdiger Hehlmann (R)

III. Medizinische Klinik, Universität Heidelberg, Mannheim, Germany.

Michael Deininger (M)

Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT, USA.

Markus Pfirrmann (M)

Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), Ludwig-Maximilians-Universität München, Munich, Germany.

Dietger Niederwieser (D)

School of Medicine, University Leipzig, Leipzig Germany.
Lithuanian University of Health Sciences, Kaunas, Lithuania.
Aichi Medical University, NagakuteAichi/Nagoya, Japan.
ORCID: 0000-0002-4737-1103

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › No advantage of Imatinib in combination with...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › No advantage of Imatinib in combination with...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › No advantage of Imatinib in combination with...
questionsmedicales.fr › Composés chimiques organiques › Amides › Urée › Hydroxy-urée › No advantage of Imatinib in combination with...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrimidines › Mésilate d'imatinib › No advantage of Imatinib in combination with...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Leucémie myéloïde chronique BCR-ABL positive › No advantage of Imatinib in combination with...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › No advantage of Imatinib in combination with...